Biosimilar Interleukins Market Trends Are Creating New Opportunities For Industry Leaders
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Biosimilar Interleukins Market CAGR Analysis And Future Market Development
The market for biosimilar interleukins has seen remarkable expansion over the last few years, with its value projected to climb from $7.52 billion in 2025 to $10.54 billion in 2026, reflecting a compound annual growth rate (CAGR) of 40.2%. This historical growth has been driven by several key factors, including the steep pricing of original interleukin biologics, a rising incidence of autoimmune and inflammatory conditions, an escalating toll from rheumatoid arthritis and psoriasis, restricted patient access to biologic treatments, and growing knowledge about biologics used for immune modulation.
The biosimilar interleukins market is projected to experience remarkable expansion in the coming years, with its value anticipated to reach $41.22 billion by 2030, representing a compound annual growth rate (CAGR) of 40.6%. This forecasted growth is driven by several key factors, including the expiration of patents on branded interleukins, the broadening of biosimilar clinical pipelines, heightened physician confidence in biosimilars, favorable governmental initiatives encouraging their adoption, and a growing need for cost-effective biologic treatments in oncology and immunology. Notable trends shaping this period include a greater embrace of biosimilar interleukins for managing autoimmune diseases, a rising preference for affordable alternatives to original biologics, an increase in regulatory approvals for biosimilars across diverse therapeutic areas, expanded applications of interleukins in chronic inflammatory conditions, and enhanced regulatory frameworks designed to facilitate biosimilar uptake.
Download A Free Sample Report For Comprehensive Market Insights:
Biosimilar Interleukins Market Growth Drivers: What Factors Are Accelerating Expansion?
The growing occurrence of autoimmune conditions like psoriasis and rheumatoid arthritis is anticipated to propel the expansion of the interleukin biosimilars market during the forecast period. Autoimmune diseases arise when immune cells fail to differentiate healthy cells from harmful antibodies. Biologic treatments, including anti-interleukin antibodies, have demonstrated substantial clinical advantages in regulating cells and directing their proliferation, activation, and migration. In February 2024, for example, reports from the National Institutes of Health (NIH), a US-based biomedical research entity, indicated that the global incidence and prevalence of autoimmune diseases are projected to rise by 19.1% and 12.5% annually, respectively. Consequently, the rising prevalence of these disorders is fueling demand for biosimilar interleukins, which is expected to drive market growth.
Biosimilar Interleukins Market Segmentation Trends And Revenue Drivers
The biosimilar interleukins market covered in this report is segmented –
1) By Type: IL-17, IL-23, IL-1, IL-5, IL-6
2) By Application: Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease (IBD), Other Applications
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Clinics, Research Institutes
Subsegments:
1) By IL-17: Autoimmune Disease Treatment, Inflammatory Disease Management
2) By IL-23: Psoriasis Treatment, Inflammatory Bowel Disease (IBD) Treatment
3) By IL-1: Rheumatoid Arthritis Management, Other Autoimmune Disorders
4) By IL-5: Asthma Treatment, Eosinophilic Disorders
5) By IL-6: Rheumatoid Arthritis Management, Inflammatory Disease Treatment
Biosimilar Interleukins Market Trends: What Is Shaping Future Industry Growth?
Key players in the biosimilar interleukins market are focusing on the development of novel products like Tofidence (tocilizumab-bavi) to enhance their competitive position and financial performance. This monoclonal antibody works by binding to interleukin-6 receptors and is utilized in managing several inflammatory autoimmune conditions. A significant milestone occurred in September 2023 when Biogen Inc., a US-based biotechnology firm, secured FDA approval for Tofidence as the first biosimilar counterpart to Genentech’s Actemra (tocilizumab). Delivered via intravenous infusion, this treatment has been authorized for addressing severe active rheumatoid arthritis, along with polyarticular juvenile idiopathic arthritis and systemic juvenile idiopathic arthritis.
Biosimilar Interleukins Market Industry Leaders: Which Organizations Are Driving Competition?
Major companies operating in the biosimilar interleukins market are Mabpharm Limitied, Gedeon Richter plc, Bio-Thera Solutions Ltd., Sunshine Guojian Pharmaceutical, Stada Arzneimittel AG, Teva Pharmaceutical Industries, 3SBio Inc., Shanghai Fosun Pharmaceuticals, Novartis AG, Pfizer Inc., Amgen Inc., F. Hoffmann-La Roche AG, Sanofi SA, Merck & Co. Inc., GlaxoSmithKline plc, Eli Lilly and Company, AstraZeneca plc, Qilu Pharmaceutical, Tonghua Dongbao, PROBIOMED S.A. de C.V., Biosidus S.A., LG Life Sciences, Viatris Inc.
Access The Complete Biosimilar Interleukins Market Report:
Biosimilar Interleukins Market Regional Outlook: Where Are The Largest Opportunities Located?
North America was the largest region in the biosimilar interleukins market in 2025. The regions covered in the biosimilar interleukins market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
